Drug
Sacituzumab govitecan clinical trials
Also written Trodelvy, IMMU-132 and GS-0132.
Keep track of what changes. Save the sacituzumab govitecan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
103 studies that test it; most in 2024 (21)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 6 |
| 2020 | 6 |
| 2021 | 11 |
| 2022 | 7 |
| 2023 | 13 |
| 2024 | 21 |
| 2025 | 17 |
| 2026 | 15 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 30 · Other 73
Gilead Sciences (22) · National Cancer Institute (NCI) (6) · MedSIR (4) · Yale University (3) · M.D. Anderson Cancer Center (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · Hoffmann-La Roche (3) · UNICANCER (2)
Often tested with
Tested in the same studies.
Trastuzumab deruxtecan (9) · Zimberelimab (6) · Pembrolizumab (5) · Enfortumab vedotin (5) · Atezolizumab (5) · Domvanalimab (4) · Carboplatin (4) · Gemcitabine (4)
Studies
Open first, then newest update. How each study uses sacituzumab govitecan is read from its arms, and is right about nine times in ten.
Testing it · 103
- Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerRecruitingPhase 3Gilead SciencesNCT06801834Written as Sacituzumab Govitecan (SG)
- Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06311214Written as Sacituzumab Govitecan
- Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance TherapyRecruitingPhase 2National Cancer Institute (NCI)NCT07504588Written as Sacituzumab Govitecan
- Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)RecruitingPhase 3Gilead SciencesNCT05633654Written as Sacituzumab govitecan-hziy (SG)
- Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)RecruitingPhase 2SWOG Cancer Research NetworkNCT07393555Written as Sacituzumab Govitecan
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Sacituzumab Govitecan
- First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.RecruitingPhase 2Nathalie LevasseurNCT07299409Written as Sacituzumab Govitecan (SG)
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerRecruitingPhase 3National Cancer Institute (NCI)NCT06524544Written as Sacituzumab Govitecan
- Sacituzumab Govitecan for Advanced Esophageal Squamous Cell CarcinomaRecruitingPhase 2National Taiwan University HospitalNCT06329869Written as Sacituzumab govitecan
- Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07825753Written as Sacituzumab govitecan (SG)
- Sacituzumab govitEcan in THYroid CancersRecruitingPhase 2Grupo Espanol de Tumores NeuroendocrinosNCT06235216Written as Sacituzumab govitecan
- A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial TumorsRecruitingPhase 2Georgetown UniversityNCT06248515Written as Sacituzumab govitecan-hziy
- Sacituzumab Govitecan and Q901 in Advanced TNBCNot yet recruitingPhase 2Yonsei UniversityNCT07788222Written as Sacituzumab govitecan and Q901
- Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBCRecruitingPhase 2Reshma L. Mahtani, D.O.NCT06263543Written as Sacituzumab govitecan
- NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast CancerNot yet recruitingPhase 3Women's Cancer Study Group GmbHNCT07178730Written as Sacituzumab govitecan
- Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast CancerNot yet recruitingPhase 2UNICANCERNCT07151586Written as Sacituzumab Govitecan / Trastuzumab Deruxtecan
- Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerRecruitingPhase 2Bindu R PotugariNCT07339059Written as Sacituzumab govitecan
- A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical CancerRecruitingPhase 2Yale UniversityNCT05838521Written as Sacituzumab govitecan
- Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder CancerRecruitingPhase 1Shilpa Gupta, MDNCT05833867Written as Sacituzumab govitecan
- Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland CancersRecruitingPhase 2M.D. Anderson Cancer CenterNCT05884320Written as Sacituzumab Govitecan
See all 103 studies that test sacituzumab govitecan →
Given in every arm · 20 — sacituzumab govitecan is usual care beside what is tested
- Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...RecruitingPhase 2National Cancer Institute (NCI)NCT06161532Written as Sacituzumab govitecan
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerRecruitingPhase 2National Cancer Institute (NCI)NCT03606967Written as Sacituzumab Govitecan
- Study of AVZO-021 in Patients With Advanced Solid TumorsRecruitingPhase 1/2Avenzo Therapeutics, Inc.NCT05867251Written as Sacituzumab Govitecan-hziy
- Study of GS-0201 Alone and in Combination in Participants With Advanced Solid TumorsRecruitingPhase 1Gilead SciencesNCT06167317Written as Sacituzumab Govitecan
- NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)RecruitingPhase 3Women's Cancer Study Group GmbHNCT06081244Written as Sacituzumab govitecan
- Sacituzumab Govitecan In TNBCRecruitingPhase 2Massachusetts General HospitalNCT04230109Written as Sacituzumab Govitecan
- Saci Nivo Rela for TNBCRecruitingPhase 1/2Yale UniversityNCT06963905Written as Sacituzumab Govitecan (SG)
- Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.RecruitingPhase 3Fundación GECPNCT06431633Written as Sacituzumab govitecan
- Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBCRecruitingPhase 2Dana-Farber Cancer InstituteNCT04468061Written as Sacituzumab Govitecan
- Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard TherapyRecruitingPhase 1Henry Ford Health SystemNCT06065371Written as Sacituzumab govetican
- Sacituzumab Govitecan Plus EV in Metastatic UCRecruitingPhase 1/2Dana-Farber Cancer InstituteNCT04724018Written as Sacituzumab Govitecan (SG)
- A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)Active, not recruitingPhase 2EMD Serono Research & Development Institute, Inc.NCT05327530Written as Sacituzumab Govitecan (SG)
- Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)Active, not recruitingPhase 2Gilead SciencesNCT05186974Written as Sacituzumab Govitecan-hziy (SG)
- Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid MalignanciesTerminatedPhase 1Gilead SciencesNCT05006794Written as sacituzumab govitecan-hziy
- Study of IDE397 in Participants With Solid Tumors Harboring MTAP DeletionActive, not recruitingPhase 1IDEAYA BiosciencesNCT04794699Written as Sacituzumab govitecan
- Study of DF1001 in Patients With Advanced Solid TumorsCompletedPhase 1/2Dragonfly TherapeuticsNCT04143711Written as Sacituzumab Govitecan-hziy
- Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBCActive, not recruitingPhase 2Ana C Garrido-Castro, MDNCT04448886Written as Sacituzumab Govitecan
- Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast CancerTerminatedPhase 2Gilead SciencesNCT04958785Written as Sacituzumab Govitecan-hziy
- Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate CancerCompletedPhase 1/2Arcus Biosciences, Inc.NCT04381832Written as SG
- A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)TerminatedPhase 1/2pharmaand GmbHNCT03992131Written as Sacituzumab govitecan
As the comparator · 5 — what is tested is compared with sacituzumab govitecan
- YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast CancerRecruitingPhase 3MediLink Therapeutics (Suzhou) Co., Ltd.NCT07461454Written as Sacituzumab govitecan
- A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of CareRecruitingPhase 3Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT07533123Written as Sacituzumab Govitecan for Injection
- Organoid-based Functional Precision Therapy for Advanced Breast CancerRecruitingPhase 2Guangdong Provincial People's HospitalNCT06102824Written as Sacituzumab govitecan
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial CancerActive, not recruitingPhase 3National Cancer Institute (NCI)NCT04579224Written as Sacituzumab Govitecan
- P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .WithdrawnPhase 2Veru Inc.NCT05008510Written as Sacituzumab Govitecan-hziy
Codes
What other systems call sacituzumab govitecan · ClinicalTrials.gg INT000470
- MeSH (NLM) C000608132sacituzumab govitecanConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) M9BYU8XDQ6SACITUZUMAB GOVITECANConfirmed FDA, NLM, Wikidata
- RxNorm 2360232One source FDA
- Wikidata Q23901469sacituzumab govitecanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C102783Sacituzumab GovitecanOne source FDA
- DrugBank DB12893One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000608132 | sacituzumab govitecan | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | M9BYU8XDQ6 | SACITUZUMAB GOVITECAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2360232 | — | One source FDA |
| Wikidata | Q23901469 | sacituzumab govitecan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C102783 | Sacituzumab Govitecan | One source FDA |
| DrugBank | DB12893 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.